Regulatory T (T) cells are essential to maintain immune homeostasis in the intestine and T cell dysfunction is associated with several inflammatory and autoimmune disorders including inflammatory bowel disease (IBD). Efforts using low-dose (LD) interleukin-2 (IL-2) to expand autologous T cells show therapeutic efficacy for several inflammatory conditions. Whether LD IL-2 is an effective strategy for treating patients with IBD is unknown. Recently, we demonstrated that LD IL-2 was protective against experimental colitis in immune humanized mice in which human CD4 T cells were restricted to human leukocyte antigen (HLA). Whether HLA restriction is required for human T cells to ameliorate colitis following LD IL-2 therapy has not been demonstrated. Here, we show that treatment with LD IL-2 reduced 2,4,6-trinitrobenzensulfonic acid (TNBS) colitis severity in NOD. (NSG) mice reconstituted with human CD34 hematopoietic stem cells. These data demonstrate the utility of standard immune humanized NSG mice as a pre-clinical model system to evaluate therapeutics targeting human T cells to treat IBD.
Copyright © 2021 Tyagi, Jacobse, Li, Allaman, Otipoby, Sampson, Wilson and Goettel.